Immunovaccine | BMIX | BioCryst | Franc-Yen | Horses
"Not another shot of Crown"?
?NEW YORK -- Show me a favorite and I will show you a loser.?
?
?This week I bought more
West Kirkland Mining after a decent breakdown of likely cost and profit scenarios -- cash-flow-and-carry -- ?for 3 Hills and Hasbrouck gold projects in central Nevada. It is WKM in Canada. WKM had mega-large trading volume this week, and I think I know why.
THE CALANDRA REPORT: Please SubscribeNow $139 yearly!
Today (
Friday in the west, Saturday in the east) ?I bought more
Immunovaccine. It is a Halifax, Canada, developer of a delivery method that uses a needle, oil and hopefully, cancer-battling antigens. Cheap anyway -- I mean both the stock and the lab's possible treatments for a range of deadly cancers. IMV in Canada.
I know the IMV principals: Canada, United Kingdom?, USA. Information upon request and please see our
TCR references.
The other thing I have in the
immuno area -- and no, I do not own KITE or JUNO or any of the dearly priced hype out there -- is
BioCryst Pharma, which is approaching a fresh high of $1 billion market value. Almost everything else out there, except for Immunovaccine, is selling for a tyrant's ransom in this biotechnical surge?. BioCryst is BCRX in USA.
I bought more
U.S. Oil Sands today. USO in Canada. It is working the Utah oil sands like that other own I own, American Sands Energy (AMSE in USA). The markets are giving this stuff away right now. USO trades like citrus juice.
Franc-yen thing: This is
Tony G. in Florida, updating us on our Swiss franc-Japanese yen confirmation, or lack of so far actually, of a gold rally. Remember
that piece of inquisition? It is at
thomcalandra.com for your reference, TCR family.
"The ratio between the yen/Swiss franc tested that 3-year downtrend resistance line three months ago and failed to follow though. (
That is, we are looking for a lower franc price and a higher yen price in cross-exchange as a way of confirming professional traders' return to gold.) Then it turned back down," says Mr. Giallourakis. "I expected it to base in May and re-test the downtrend line, but it hasn't."
Gold, alas, did not surpass $1,220 USD an ounce a couple of weeks ago and is retesting its home base again at $1,180 or so.
A re-test and breakout of the yen/Swiss franc ratio's downtrending line is what Tony G. is looking for to confirm a gold rally. That breakout level is now just under .00080. It was at 0.0083 in March.
Our
TCR family member and perhaps future big-?time hedge fund operator notes, "This downtrend resistance line has been in place for more than 3 years, so when it finally is broken, it should be accompanied by a move higher in the dollar price of gold."
Today's closing price of Yen/Swiss Franc was 0.00748.
Chart is just above us in this report.
Belmont Stakes: I like
Materiality to win in this
Triple Crown thoroughbred horseracing event Saturday in Queens, NYC. What can I say? Show me a favorite and I will show you a sniper, er, I mean a pharaoh. What I'm really wanting now is
notanother shot of (Triple) Crown.
Hey, bartender ...
Have you read between the lines of this
latest TCR report, delivered earlier in the week?
Please see:Cambodia'sHalo Effect. [
Photo here: Angkor Gold's
Delayne Weeks of Grande Prairie, Alberta, reviews the Mesco Gold Mine headframe in place at Phum Syarung, Cambodia.]
At the close of that report, I give
Brazil Minerals CEO
Marc Fogassawhat-for. Are you listening, M-F? It is this incessant fractionalizing of BMIX stock as
tens of millions of shares change hands in the USA over-the-counter marketplace. Read it, and if you think something
fughazy is going on with Mr. Fogassa and the way he and his company are trip-wiring the stock with debt for equity, and then way-cheap stock for execs' salary, call your local
fughazy-snapper and tell her or him the Brazilian CEO lives in southern California. I still own every fractional penny of BMIX I ever bought -- on a heads-up from
TCR family member and former (briefly) Brazil Minerals financial officer Joseph Ramelli. So far, I am not feeling very heads-up about that one.
Aside from BMIX, and yes, I know, I know, we are still waiting for substantial sales contracts from SYSOREX GLOBAL (NASDAQ SYRX), aside from those, and yes, I acknowledge, the
Bitterroot Resources glop that I still wear on my portfolio, we are making money.
-- Thom Calandra
THE CALANDRA REPORT: Subscribe
Now $139 yearly!
See: a thomcalandra.com home for our expanding TCR family.
THE CALANDRA REPORT
$139: Will Recur Yearly
Thom Calandra & TCR are researchers and investors. They are not registered investment advisers. The research and material they offer to subscribers are meant as editorial opinion.